Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies

This study has been completed.
Sponsor:
Collaborators:
Actinium Pharmaceuticals
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center.
ClinicalTrials.gov Identifier:
NCT00672165
First received: May 2, 2008
Last updated: February 24, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2015
  Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)